Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“MediLink announced collaboration and licensing agreement with Roche for YL201, an ADC targeting B7H3 with YL0010014 Topo1i payload (TMALIN ADC platform).
Roche previously (Jan 2024) initiated another collaboration with MediLink for YL211 (c-Met ADC with same drug-linker).
YL201 phase 1/1b in advance solid tumors.
YL201 MTD was determined to be 2.8 mg/kg Q3W and the recommended expansion doses were selected as 2.0 mg /kg and 2.4 mg/kg.
Phase 3 ongoing in China (SCLC and NPC).
‘no significant correlation was observed between B7H3 expression and the clinical response across different tumor types'”
Title: A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Authors: Yuxiang Ma, Yunpeng Yang, Yan Huang, Wenfeng Fang, Jinhui Xue, Xiangjiao Meng, Yun Fan, Siqing Fu, Lin Wu, Yulong Zheng, Jian Liu, Zhihua Liu, Wu Zhuang, Seth Rosen, Song Qu, Bihui Li, Mingjun Li, Yanqiu Zhao, Shujun Yang, Yinghua Ji, David Sommerhalder, Suxia Luo, Kunyu Yang, Jingao Li, Dongqing Lv, Peng Zhang, Yuanyuan Zhao, Shaodong Hong, Yang Zhang, Shen Zhao, Steve Chin, Xian Zhang, Wei Lian, Jiaqiang Cai, Tongtong Xue, Li Zhang, Hongyun Zhao
Read the Full Article on Nature Medicine
More posts featuring Raffaele Colombo.
